Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ryohei Yoshino"'
Autor:
Hiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, Norio Itokawa, Ryohei Yoshino, Kentaro Fujimoto, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Ryuta Kojima, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Ei Itobayashi, Masanori Atsukawa, Jun Kato, Naoya Kato
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 513-520 (2023)
Abstract Background Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecula
Externí odkaz:
https://doaj.org/article/48e468f6fb3749d39b8be35352b06933
Autor:
Hiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, Norio Itokawa, Ryohei Yoshino, Kentaro Fujimoto, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Ryuta Kojima, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Jun Kato, Naoya Kato
Background: Cabozantinib was found to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecular target agents as the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2624578d39719767d6cbb3fa57d8b38
https://doi.org/10.21203/rs.3.rs-2655181/v1
https://doi.org/10.21203/rs.3.rs-2655181/v1
Publikováno v:
The Proceedings of Conference of Hokuriku-Shinetsu Branch. :208-1
Publikováno v:
The Proceedings of Mechanical Engineering Congress, Japan. 2014:J0470203